---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-205600"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T00:43:47.961874+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Madrigal submits resmetirom NDA for NASH; cash $298.4M as of June 30

## Summary
- Resmetirom NDA submitted to FDA for accelerated approval of NASH with liver fibrosis.
- Cash, cash equivalents and marketable securities $298.4M at June 30, 2023, down from $358.8M at Dec 31, 2022.
- Operating expenses for six months ended June 30, 2023: $164.8M (R&D $130.8M, G&A $34.0M), up from $127.9M in prior year.
- Interest income $7.3M and interest expense $5.2M for six months; cash used in operations $159.4M.
- ICER final report indicates resmetirom may be cost-effective for at-risk NASH; disease education campaigns launched.

## SEC filing metadata
- accession: 0001193125-23-205600
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312523205600/0001193125-23-205600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312523205600/d542332d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-205600
- JSON: https://secwatch.observer/filing/0001193125-23-205600.json
- Plain text: https://secwatch.observer/filing/0001193125-23-205600.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.